BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $37,217,213 | -20.6% | 5,286,536 | -5.9% | 0.04% | -25.4% |
| Q1 2023 | $46,857,222 | +77125.3% | 5,618,372 | +6.3% | 0.06% | -33.0% |
| Q4 2022 | $60,676 | -99.9% | 5,285,348 | +9.8% | 0.09% | -2.2% |
| Q3 2022 | $60,653,000 | -5.2% | 4,813,772 | -20.4% | 0.09% | +1.1% |
| Q2 2022 | $63,977,000 | -23.0% | 6,046,961 | +18.4% | 0.09% | -5.3% |
| Q1 2022 | $83,038,000 | +18.6% | 5,106,903 | +1.0% | 0.09% | +34.3% |
| Q4 2021 | $70,015,000 | +40606.4% | 5,055,264 | +42150.4% | 0.07% | – |
| Q3 2021 | $172,000 | – | 11,965 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |